New clinical trials for mesothelioma drug

October 29, 2013 at 4:41 PM

A recently launched, international clinical trial that involves the targeted killing of mesothelioma cancer stem cells soon could provide a much-needed breakthrough for patients around the world.

The mesothelioma trial, which is expected to involve 350-400 patients across 11 countries, will study the cancer stem cell inhibitor defactinib (VS-6063), which has shown considerable promise in treating other cancers.

Read more.